IRUS Total

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

File Description SizeFormat 
1-s2.0-S1473309922002717-main.pdfPublished version1.24 MBAdobe PDFView/Open
Title: Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
Authors: Munro, APS
Feng, S
Janani, L
Cornelius, V
Aley, PK
Babbage, G
Baxter, D
Bula, M
Cathie, K
Chatterjee, K
Dodd, K
Enever, Y
Qureshi, E
Goodman, AL
Green, CA
Harndahl, L
Haughney, J
Hicks, A
Van der Klaauw, AA
Kanji, N
Libri, V
Llewelyn, MJ
McGregor, AC
Maallah, M
Minassian, AM
Moore, P
Mughal, M
Mujadidi, YF
Holliday, K
Osanlou, O
Osanlou, R
Owens, DR
Pacurar, M
Palfreeman, A
Pan, D
Rampling, T
Regan, K
Saich, S
Bawa, T
Saralaya, D
Sharma, S
Sheridan, R
Thomson, EC
Todd, S
Twelves, C
Read, RC
Charlton, S
Hallis, B
Ramsay, M
Andrews, N
Lambe, T
Nguyen-Van-Tam, JS
Snape, MD
Liu, X
Faust, SN
COV-BOOST study group
Item Type: Journal Article
Abstract: BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19. METHODS: The COV-BOOST trial is a multicentre, blinded, phase 2, randomised controlled trial of seven COVID-19 vaccines given as third-dose boosters at 18 sites in the UK. This sub-study enrolled participants who had received BNT162b2 (Pfizer-BioNTech) as their third dose in COV-BOOST and randomly assigned them (1:1) to receive a fourth dose of either BNT162b2 (30 μg in 0·30 mL; full dose) or mRNA-1273 (Moderna; 50 μg in 0·25 mL; half dose) via intramuscular injection into the upper arm. The computer-generated randomisation list was created by the study statisticians with random block sizes of two or four. Participants and all study staff not delivering the vaccines were masked to treatment allocation. The coprimary outcomes were safety and reactogenicity, and immunogenicity (anti-spike protein IgG titres by ELISA and cellular immune response by ELISpot). We compared immunogenicity at 28 days after the third dose versus 14 days after the fourth dose and at day 0 versus day 14 relative to the fourth dose. Safety and reactogenicity were assessed in the per-protocol population, which comprised all participants who received a fourth-dose booster regardless of their SARS-CoV-2 serostatus. Immunogenicity was primarily analysed in a modified intention-to-treat population comprising seronegative participants who had received a fourth-dose booster and had available endpoint data. This trial is registered with ISRCTN, 73765130, and is ongoing. FINDINGS: Between Jan 11 and Jan 25, 2022, 166 participants were screened, randomly assigned, and received either full-dose BNT162b2 (n=83) or half-dose mRNA-1273 (n=83) as a fourth dose. The median age of these participants was 70·1 years (IQR 51·6-77·5) and 86 (52%) of 166 participants were female and 80 (48%) were male. The median interval between the third and fourth doses was 208·5 days (IQR 203·3-214·8). Pain was the most common local solicited adverse event and fatigue was the most common systemic solicited adverse event after BNT162b2 or mRNA-1273 booster doses. None of three serious adverse events reported after a fourth dose with BNT162b2 were related to the study vaccine. In the BNT162b2 group, geometric mean anti-spike protein IgG concentration at day 28 after the third dose was 23 325 ELISA laboratory units (ELU)/mL (95% CI 20 030-27 162), which increased to 37 460 ELU/mL (31 996-43 857) at day 14 after the fourth dose, representing a significant fold change (geometric mean 1·59, 95% CI 1·41-1·78). There was a significant increase in geometric mean anti-spike protein IgG concentration from 28 days after the third dose (25 317 ELU/mL, 95% CI 20 996-30 528) to 14 days after a fourth dose of mRNA-1273 (54 936 ELU/mL, 46 826-64 452), with a geometric mean fold change of 2·19 (1·90-2·52). The fold changes in anti-spike protein IgG titres from before (day 0) to after (day 14) the fourth dose were 12·19 (95% CI 10·37-14·32) and 15·90 (12·92-19·58) in the BNT162b2 and mRNA-1273 groups, respectively. T-cell responses were also boosted after the fourth dose (eg, the fold changes for the wild-type variant from before to after the fourth dose were 7·32 [95% CI 3·24-16·54] in the BNT162b2 group and 6·22 [3·90-9·92] in the mRNA-1273 group). INTERPRETATION: Fourth-dose COVID-19 mRNA booster vaccines are well tolerated and boost cellular and humoral immunity. Peak responses after the fourth dose were similar to, and possibly better than, peak responses after the third dose. FUNDING: UK Vaccine Task Force and National Institute for Health Research.
Issue Date: Aug-2022
Date of Acceptance: 19-Apr-2022
URI: http://hdl.handle.net/10044/1/98005
DOI: 10.1016/S1473-3099(22)00271-7
ISSN: 1473-3099
Publisher: Elsevier
Start Page: 1131
End Page: 1141
Journal / Book Title: Lancet Infectious Diseases
Volume: 22
Issue: 22
Copyright Statement: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Sponsor/Funder: National Institute for Health Research
Funder's Grant Number: COV-BOOST
Keywords: COV-BOOST study group
1103 Clinical Sciences
1108 Medical Microbiology
1117 Public Health and Health Services
Publication Status: Published
Conference Place: United States
Online Publication Date: 2022-05-09
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine
Imperial College London COVID-19
School of Public Health

This item is licensed under a Creative Commons License Creative Commons